Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 121,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

References
(1)  San Antonio Breast Cancer Symposium. SABCS Annual '11 Meeting Program. Available at http://www.sabcs.org/ProgramSchedule/index.asp. Accessed November 2011.

(2)  American Society of Hematology. ASH Annual '11 Meeting Program. Available at http://ash.confex.com/ash/2011/webprogram/start.html. Accessed November 2011.

(*) Novartis and Incyte Corporation have a worldwide collaboration and licensing agreement for INC424.

(**)Known as Glivec® (imatinib) outside the US, Canada and Israel.

(#) Rapamune® (sirolimus) and Torisel® (temsirolimus) are registered trademarks of Wyeth Pharmaceuticals Inc.

(***) Known as Aclasta outside the US.

 

 Novartis Media Relations 

 

 Media only:Investors only:Amy VinciRichard JarvisNovartis OncologyNovartis CorporationP: +1 862 778 6309P: +1 212 830 2433M: +1 917 535 2602

investor.relations@novartis.com 

 Dana Kahn Cooper P: +1 732 817 1800

 F: +1 732 817 1834

  

  

For Novartis multimedia content, please
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
9. Novartis Class Awarded $250 Million in Punitive Damages
10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SPRING, Md. , Dec. 24, 2014  United Therapeutics ... Medtronic, Inc. (NYSE: MDT ) has submitted ... Drug Administration (FDA) for the use of Medtronic,s SynchroMed ... newly developed catheter) for use with United Therapeutics, Remodulin ...
(Date:12/24/2014)... 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... clinical grade hypothermic storage and cryopreservation freeze ... cells and tissues  ("BioLife" or the "Company"), today announced that ... May 4, 2015 (the "Annual Meeting"). Because the ...
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 Earlier this ... L. Sherley, director of the Adult Stem Cell Technology Center, ... and under appreciated unique property of adult tissue stem cells. ... in the Past, Important for the Future,” embodied the essence ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 According to Ross ... Island Affiliate of ITRA Global, the national office market continues ... recovery. This is evidenced by the third quarter’s surprising ... market. Low energy costs have held inflation down and ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... in the question, if the entry of veterinary medicinal ... environmental relevance. In a recent study, published in the ... now focused on the so far less investigated benzimidazole ... data set on fate and behavior of veterinary medicinal ...
... American Society of,Hematology (ASH) will host its annual ... Center on Friday, December 7, 2007, beginning at,8:00 ... in hematology,the biological sciences, and medical research, is ... This year, students will have the,opportunity to explore ...
... Cost, Savings and Avoidance of Approximately $1.5 Billion by 2010 and Incur, Associated ... ... 11% Increase in Indicative Dividend for 2008 and Declares ... Quarterly Dividend, * Revises 2007 Full-Year GAAP EPS Guidance to ...
Cached Biology Technology:New insights into the fate of anti-parasitics in manure and manured soils 2ASH Holds a Special Symposium to Interest High School Students in Biomedical Research 2Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 2Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 3Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 4Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 5Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 6Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 7Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 8Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 9Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 10Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 11
(Date:12/17/2014)...  HITLAB SM announced today its completion of a ... to current U.S. Food and Drug Administration (FDA) regulations. ... and smart phone application trials utilizing the highest principles ... is determined to improve global healthcare access, quality, and ...
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced the ... report to their offering. ... in this market is the increasing demand for medical ... of patient data for quick and correct diagnosis during ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology used for ... overall facial feature of a person such as nose, ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... in grain crops should be expanded to include so-called ... forms in the body, a new study concludes. It ... . Chiara Dall,Asta and colleagues explain that molds ... toxic substances termed mycotoxins. Some health experts regard mycotoxins ...
... promises to allow expanded use of a mainstay biological ... pest-resistance concerns of traditional insecticides, scientists are reporting. The ... technique (SIT) appears in the journal ACS Synthetic ... the Lepidoptera, a large family of insects with a ...
... of Manchester is leading the way when it comes to ... training package to teach students and scientists how to best ... hoped it will encourage more researchers working on a range ... humble fly. The unique scheme has been put together ...
Cached Biology News:World first for fly research 2World first for fly research 3
...
...
... filters allow for the rapid isolation of DNA ... gel slice in the spin filter, centrifuge for ... is recovered. There is no need to melt ... filters can also be used for buffer exchange, ...
ChemiArray Human Cytokine Antibody Array VII, 60 cytokines per membrane...
Biology Products: